Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin

A. Stiekema; Q. Boldingh; C. Korse; V. van der Noort; H. Boot; W. van Driel; G.G. Kenter; C.A.R. Lok

doi:10.1016/j.ygyno.2014.12.037

Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin

A. Stiekema, Q. Boldingh, C. Korse, V. van der Noort, H. Boot, W. van Driel, G.G. Kenter, C.A.R. Lok

Obstetrics and gynaecology

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	562-566
Journal	Gynecologic Oncology
Volume	136
Issue number	3
DOIs	https://doi.org/10.1016/j.ygyno.2014.12.037
Publication status	Published - 2015

Access to Document

10.1016/j.ygyno.2014.12.037

Cite this

@article{4fdfece5a0044eed8e88cd7c8ba64d5e,

title = "Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin",

author = "A. Stiekema and Q. Boldingh and C. Korse and {van der Noort}, V. and H. Boot and {van Driel}, W. and G.G. Kenter and C.A.R. Lok",

year = "2015",

doi = "10.1016/j.ygyno.2014.12.037",

language = "Undefined/Unknown",

volume = "136",

pages = "562--566",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "3",

}

TY - JOUR

T1 - Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin

AU - Stiekema, A.

AU - Boldingh, Q.

AU - Korse, C.

AU - van der Noort, V.

AU - Boot, H.

AU - van Driel, W.

AU - Kenter, G.G.

AU - Lok, C.A.R.

PY - 2015

Y1 - 2015

U2 - 10.1016/j.ygyno.2014.12.037

DO - 10.1016/j.ygyno.2014.12.037

M3 - Article

C2 - 25560808

SN - 0090-8258

VL - 136

SP - 562

EP - 566

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 3

ER -